 | |
| Clinical data | |
|---|---|
| Other names | Oxanoribogaine |
| Drug class | Atypicalκ-opioid receptorpartial agonist |
| Identifiers | |
| |
| PubChemCID | |
| Chemical and physical data | |
| Formula | C19H23NO2 |
| Molar mass | 297.398 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Oxa-noribogaine is an atypicalκ-opioid receptoragonist of the "oxa-iboga" family and asyntheticbenzofurananalogue ofnoribogaine.[1][2][3] Although it still binds tohERG with similar avidity as noribogaine, it appears to be devoid of theproarrhythmicside effects of noribogaine.[1][3]
The drug hasanalgesic effects as apotent atypical κ-opioid receptorpartial agonist and, opposed to typical κ-opioid receptoragonists, is characterized by the absence ofpro-depressant effects.[1][3] It induces a robust κ-opioid receptor-dependent increase inGDNF protein levels in theventral tegmental area andmedial prefrontal cortex.[1][3] After a single dose or short-term treatment, oxa-noribogaine induces long-lasting suppression ofopioiddrug-seeking behavior in rodentrelapsemodels.[1][3] It also counteracts persistentopioid-induced hyperalgesia.[3]
Oxa-noribogaine was first described in the literature in 2015,[4] and was then further described in 2024.[1][5][2][3]
 | Thispsychoactive drug-related article is astub. You can help Wikipedia byexpanding it. |